1. De-novo nonalcoholic fatty liver disease at 5 years after liver transplantation: prevalence and predictive factors
- Author
-
Laura Hernandez Gómez, Javier Tejedor-Tejada, Rodrigo Nájera Muñoz, Gloria Sánchez-Antolín, Esteban Fuentes Valenzuela, Carmen Alonso-Martín, Fátima Sánchez-Martín, Félix García-Pajares, and Carolina Almohalla Álvarez
- Subjects
Liver Cirrhosis ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,Liver transplantation ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Fibrosis ,Non-alcoholic Fatty Liver Disease ,Risk Factors ,Diabetes mellitus ,Internal medicine ,Nonalcoholic fatty liver disease ,medicine ,Prevalence ,Humans ,Retrospective Studies ,Hepatology ,business.industry ,nutritional and metabolic diseases ,Middle Aged ,medicine.disease ,Comorbidity ,digestive system diseases ,Liver Transplantation ,Transplantation ,Liver ,030220 oncology & carcinogenesis ,030211 gastroenterology & hepatology ,Female ,Steatosis ,Metabolic syndrome ,business - Abstract
BACKGROUND AND AIMS Nonalcoholic fatty liver disease (NAFLD) is a long-term complication after liver transplantation. Our aims were to determine de-novo-NAFLD at 5-year post-liver transplantation and identify predictive risk factors. METHODS This was a retrospective analysis of de-novo-NAFLD at 5-year post-liver transplantation. NAFLD was defined as the radiological evidence of steatosis. Data from transplanted patients between November 2001 and May 2014 were collected. Noninvasive fibrosis scores were calculated. Predictors of de-novo NAFLD and survival were assessed by multivariate analyses and Kaplan-Meier method. RESULTS A total of 252 liver transplantations were evaluated after applying exclusion criteria, (78.6% men) with 54.9 years old (SD ± 9.5). Prevalence of de-novo NAFLD at 5-year post-liver transplantation was 36.1%. Cardiovascular events were presented in 19.88% and 23.08% of non-NAFLD and NAFLD patients, (P = 0.58). On multivariate analysis, male sex (OR, 5.40; P = 0.001), obesity (OR, 3.72; P = 0.017), metabolic syndrome (OR, 4.69; P
- Published
- 2020